Sandoz will acquire Just – Evotec Biologics’ biosimilar development and manufacturing plant in Toulouse for $300m.

Arrowhead's subsidiary Visirna has entered an agreement with Sanofi for plozasiran, a potential treatment for hypertriglyceridemia.

Atombeat and BioDuro have announced a strategic partnership to launch an AI-powered platform aimed at accelerating peptide drug discovery.

Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate regulatory delays for blockbuster ophthalmology drug Eylea HD due to ...

Europe’s cannabis pharmaceutical sector is shifting as scientific rigour, regulatory clarity and cautious capital define its next chapter.

Major pharma manufacturers have a 29 September deadline to adjust their drug prices relative to other developed countries.

Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.

Just one day after CEO Stéphane Bancel’s sudden announcement of a 10% workforce reduction, Moderna has released Q2 2025 that that fell short of analyst expectations.

The FDA has approved Ascendis Pharma’s Skytrofa (lonapegsomatropin-tcgd, developed as TransCon hGH) for the treatment of adults with GHD.

GSK's Q2 results show that sales of its specialist oncology assets have risen by 42%, while general drug sales were down 6%.

MetrioPharm’s lead compound, MP1032, has received ODD from the European Medicines Agency (EMA) for treating DMD in children.

Tidmarsh will temporarily guide CBER’s regulatory activities while the FDA searches for a permanent department lead.